 | Up a level |
Cramer, P., Fraser, G., Chanan-Khan, A., Demirkan, F., Silva, Santucci R., Pylypenko, H., Grosicki, S., Janssens, A., Pristupa, A., Mayer, J., Dilhuydy, M. -S, Loscertales, J., Goy, A., Avigdor, A., Rule, S., Phelps, C., Mahler, M., Salman, M., Howes, A., Balasubramanian, S. and Hallek, M. (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Oncol. Res. Treat., 39. S. 34 - 36. BASEL: KARGER. ISSN 2296-5262
Fraser, G., Cramer, P., Demirkan, F., Silva, R. Santucci, Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M-S, Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Pavlovsky, M. A., Karlsson, C., Hallek, M., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A. and Chanan-Khan, A. (2019). Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia, 33 (4). S. 969 - 981. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551